MA54845A - Inhibiteurs de ltbp propres à un complexe de tgf-béta et leurs utilisations - Google Patents

Inhibiteurs de ltbp propres à un complexe de tgf-béta et leurs utilisations

Info

Publication number
MA54845A
MA54845A MA054845A MA54845A MA54845A MA 54845 A MA54845 A MA 54845A MA 054845 A MA054845 A MA 054845A MA 54845 A MA54845 A MA 54845A MA 54845 A MA54845 A MA 54845A
Authority
MA
Morocco
Prior art keywords
ltbp
tgf
inhibitors
complex specific
beta complex
Prior art date
Application number
MA054845A
Other languages
English (en)
Inventor
George Coricor
Abhishek Datta
Adam Fogel
Justin W Jackson
Christopher Littlefield
Thomas Schurpf
Stefan Wawersik
Original Assignee
Scholar Rock Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scholar Rock Inc filed Critical Scholar Rock Inc
Publication of MA54845A publication Critical patent/MA54845A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
MA054845A 2019-01-30 2020-01-30 Inhibiteurs de ltbp propres à un complexe de tgf-béta et leurs utilisations MA54845A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962798927P 2019-01-30 2019-01-30

Publications (1)

Publication Number Publication Date
MA54845A true MA54845A (fr) 2021-09-29

Family

ID=69423073

Family Applications (1)

Application Number Title Priority Date Filing Date
MA054845A MA54845A (fr) 2019-01-30 2020-01-30 Inhibiteurs de ltbp propres à un complexe de tgf-béta et leurs utilisations

Country Status (21)

Country Link
US (3) US11214614B2 (fr)
EP (1) EP3689905A3 (fr)
JP (1) JP2022524281A (fr)
KR (1) KR20210121174A (fr)
CN (1) CN113677711A (fr)
AR (1) AR117918A1 (fr)
AU (1) AU2020216177A1 (fr)
BR (1) BR112021015056A2 (fr)
CA (1) CA3128042A1 (fr)
CL (1) CL2021001993A1 (fr)
CO (1) CO2021010062A2 (fr)
CR (1) CR20210416A (fr)
DO (1) DOP2021000161A (fr)
EA (1) EA202192130A1 (fr)
IL (1) IL285076A (fr)
MA (1) MA54845A (fr)
MX (1) MX2021009175A (fr)
PE (1) PE20220279A1 (fr)
SG (1) SG11202108099WA (fr)
TW (1) TW202043267A (fr)
WO (1) WO2020160291A2 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3128042A1 (fr) 2019-01-30 2020-08-06 Scholar Rock, Inc. Inhibiteurs specifiques du complexe ltbp de tgfs et leurs utilisations
WO2021039945A1 (fr) 2019-08-28 2021-03-04 Chugai Seiyaku Kabushiki Kaisha Anticorps anti-tgf-bêta 1 latent inter-espèces et leurs procédés d'utilisation
BR112022013733A2 (pt) * 2020-01-11 2022-11-01 Scholar Rock Inc Inibidores de tgfbeta e uso dos mesmos
WO2022204581A2 (fr) 2021-03-26 2022-09-29 Scholar Rock, Inc. Inhibiteurs de tgf-bêta et leur utilisation
WO2022256723A2 (fr) 2021-06-03 2022-12-08 Scholar Rock, Inc. Inhibiteurs de tgf-bêta et leur utilisation thérapeutique
IL309078A (en) * 2021-06-23 2024-02-01 Scholar Rock Inc A myostatin pathway inhibitor in combination with a GLP-1 pathway activator for use in the treatment of metabolic disorders
EP4370148A1 (fr) 2021-07-14 2024-05-22 Scholar Rock, Inc. Inhibiteurs spécifiques du complexe ltbp de tgf bêta1 et leurs utilisations
WO2024187051A1 (fr) 2023-03-07 2024-09-12 Scholar Rock, Inc. Inhibiteurs de tgf-bêta destinés à être utilisés pour traiter un cancer résistant ou réfractaire chez des patients

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (fr) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Récepteurs chimériques par liaison et expression de l'ADN
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
EP0768377A1 (fr) 1988-09-02 1997-04-16 Protein Engineering Corporation Production et sélection de protéines de liaison diversifiées de recombinaison
US6291158B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for tapping the immunological repertoire
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
JPH06508511A (ja) 1990-07-10 1994-09-29 ケンブリッジ　アンティボディー　テクノロジー　リミティド 特異的な結合ペアーの構成員の製造方法
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
WO1992009690A2 (fr) 1990-12-03 1992-06-11 Genentech, Inc. Methode d'enrichissement pour des variantes de l'hormone de croissance avec des proprietes de liaison modifiees
DK1279731T3 (da) 1991-03-01 2007-09-24 Dyax Corp Fremgangsmåde til udvikling af bindende miniproteiner
DK1471142T3 (da) 1991-04-10 2009-03-09 Scripps Research Inst Heterodimere receptor-biblioteker under anvendelse af fagemider
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
ES2313867T3 (es) 1991-12-02 2009-03-16 Medical Research Council Produccion de anticuerpos anti-auto de repertorios de segmentos de anticuerpo expresados en la superficie de fagos.
US5786464C1 (en) 1994-09-19 2012-04-24 Gen Hospital Corp Overexpression of mammalian and viral proteins
US6114148C1 (en) 1996-09-20 2012-05-01 Gen Hospital Corp High level expression of proteins
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
US6492497B1 (en) 1999-04-30 2002-12-10 Cambridge Antibody Technology Limited Specific binding members for TGFbeta1
US7138496B2 (en) 2002-02-08 2006-11-21 Genetastix Corporation Human monoclonal antibodies against human CXCR4
EP1674480A4 (fr) 2003-09-04 2007-06-20 Riken Anticorps capable de reconnaitre la region de controle de l'activation de tgf-beta
EP3520815B1 (fr) 2005-02-08 2021-11-17 Genzyme Corporation Anticorps de tgfbeta
PL1874818T3 (pl) 2005-04-22 2011-09-30 Lilly Co Eli Przeciwciała swoiste wobec TGF-beta 1
US8877688B2 (en) 2007-09-14 2014-11-04 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
US20110165063A1 (en) * 2009-01-29 2011-07-07 Abbott Laboratories Il-1 binding proteins
WO2011102483A1 (fr) * 2010-02-19 2011-08-25 独立行政法人理化学研究所 ANTICORPS SE LIANT AU TGF-β DU LAP HUMAIN
KR102051014B1 (ko) * 2011-06-03 2019-12-04 조마 테크놀로지 리미티드 Tgf-베타에 특이적인 항체
WO2014074532A2 (fr) 2012-11-06 2014-05-15 Scholar Rock Inc. Compositions et procédés pour la modulation de la signalisation cellulaire
AU2014262843B2 (en) 2013-05-06 2017-06-22 Scholar Rock, Inc. Compositions and methods for growth factor modulation
TWI779010B (zh) 2014-12-19 2022-10-01 日商中外製藥股份有限公司 抗肌抑素之抗體、含變異Ｆｃ區域之多胜肽及使用方法
WO2016161410A2 (fr) 2015-04-03 2016-10-06 Xoma Technology Ltd. Traitement du cancer à l'aide d'inhibiteurs de tgf-bêta et pd-1
IL258121B2 (en) * 2015-09-15 2024-01-01 Scholar Rock Inc Antipro/latent myostatin antibodies and their uses
DK3365368T3 (da) * 2016-03-11 2023-06-26 Scholar Rock Inc Tgfbeta1-bindende immunoglobuliner og anvendelse deraf
KR20230169484A (ko) 2016-06-13 2023-12-15 스칼러 락, 인크. 미오스타틴 억제제의 용도 및 조합 요법
CN110049773A (zh) 2016-07-14 2019-07-23 供石公司 TGFβ抗体、方法和用途
US10375984B2 (en) 2016-07-18 2019-08-13 R.J. Reynolds Tobacco Company Nonwoven composite smokeless tobacco product
RU2019106663A (ru) 2016-08-12 2020-09-14 Мерк Патент Гмбх Комбинированная терапия рака
WO2018043734A1 (fr) * 2016-09-05 2018-03-08 Chugai Seiyaku Kabushiki Kaisha Anticorps anti-tgf-beta 1 et leurs procédés d'utilisation
KR20240137126A (ko) * 2017-01-06 2024-09-19 스칼러 락, 인크. 이소형-특이적, 콘텍스트-허용성 TGFβ1 억제제 및 그의 용도
SG11201906157YA (en) 2017-01-07 2019-08-27 Merck Patent Gmbh Dosing regimens and dosage forms for targeted tgf-b inhibition
EA201991729A1 (ru) 2017-01-20 2019-12-30 Санофи Антитела к tgf-бета и их применение
CA3055156A1 (fr) 2017-03-02 2018-09-07 National Research Council Of Canada Molecules de fusion d'ectodomaines du recepteur du tgf-.beta. et leurs utilisations
US20200231682A1 (en) * 2017-07-28 2020-07-23 Scholar Rock, Inc. Ltbp complex-specific inhibitors of tgf-beta 1 and uses thereof
EP3820896A1 (fr) 2018-07-11 2021-05-19 Scholar Rock, Inc. INHIBITEURS DE TGFbeta1 ET LEUR UTILISATION
JP7540994B2 (ja) 2018-07-11 2024-08-27 スカラー ロック インコーポレイテッド 高親和性のアイソフォーム選択的ＴＧＦβ１阻害剤、およびその使用
CA3128042A1 (fr) 2019-01-30 2020-08-06 Scholar Rock, Inc. Inhibiteurs specifiques du complexe ltbp de tgfs et leurs utilisations

Also Published As

Publication number Publication date
AU2020216177A1 (en) 2021-09-23
TW202043267A (zh) 2020-12-01
CL2021001993A1 (es) 2022-04-08
CR20210416A (es) 2021-09-14
MX2021009175A (es) 2021-09-14
EA202192130A1 (ru) 2021-12-28
WO2020160291A2 (fr) 2020-08-06
DOP2021000161A (es) 2021-09-15
US20220363741A1 (en) 2022-11-17
IL285076A (en) 2021-09-30
EP3689905A3 (fr) 2021-02-24
US11365245B2 (en) 2022-06-21
US20220064276A1 (en) 2022-03-03
PE20220279A1 (es) 2022-02-25
CO2021010062A2 (es) 2021-08-09
AR117918A1 (es) 2021-09-01
SG11202108099WA (en) 2021-08-30
EP3689905A2 (fr) 2020-08-05
WO2020160291A9 (fr) 2020-10-15
US20210047396A1 (en) 2021-02-18
CA3128042A1 (fr) 2020-08-06
CN113677711A (zh) 2021-11-19
WO2020160291A3 (fr) 2020-09-10
BR112021015056A2 (pt) 2022-01-11
JP2022524281A (ja) 2022-05-02
US11214614B2 (en) 2022-01-04
KR20210121174A (ko) 2021-10-07

Similar Documents

Publication Publication Date Title
MA54845A (fr) Inhibiteurs de ltbp propres à un complexe de tgf-béta et leurs utilisations
MA49690A (fr) Inhibiteurs spécifiques du complexe ltbp de tgf-bêta 1 et leurs utilisations
MA55627A (fr) Agonistes de glp-1r et leurs utilisations
MA42622A (fr) Agents de liaison à tigit et leurs utilisations
MA56462A (fr) Inhibiteurs de hpk1 et leurs utilisations
JP1705886S (ja) サーキュレーター
MA55008A (fr) Aminoacyl-arnt synthétases et leurs utilisations
ES1253929Y (es) Multiplicadora
JP1720750S (ja) 展示ケース
JP1720751S (ja) 展示ケース
JP1705516S (ja) サーキュレーター
JP1705519S (ja) サーキュレーター
JP1705518S (ja) サーキュレーター
JP1705517S (ja) サーキュレーター
JP1705515S (ja) サーキュレーター
JP1705578S (ja) サーキュレーター
JP1705504S (ja) サーキュレーター
JP1742844S (ja) カードケース
JP1727617S (ja) 棚
JP1720021S (ja) 棚
ES1248799Y (es) Maleta estanteria
JP1720016S (ja) 棚
JP1720015S (ja) 棚
TH2102004667S (th) ชั้นวางของ
CA199242S (fr) Etagère